Assuntos
Antibacterianos/uso terapêutico , Infecções Relacionadas a Cateter/terapia , Cateteres de Demora/microbiologia , Diálise Peritoneal Ambulatorial Contínua/efeitos adversos , Diálise Peritoneal Ambulatorial Contínua/instrumentação , Lavagem Peritoneal , Peritonite/terapia , Infecções Estafilocócicas/terapia , Infecções Relacionadas a Cateter/diagnóstico , Infecções Relacionadas a Cateter/microbiologia , Terapia Combinada , Contaminação de Equipamentos , Desenho de Equipamento , Humanos , Peritonite/diagnóstico , Peritonite/microbiologia , Recidiva , Infecções Estafilocócicas/diagnóstico , Infecções Estafilocócicas/microbiologia , Resultado do TratamentoRESUMO
OBJECTIVE@#To determine whether the OraQuick® HIV-1/2 Assay (OraSure Technologies, Inc., Bethlehem, PA, USA) in sputum is a valid tool for HIV surveillance among TB patients.@*METHODS@#A cross sectional study was carried out on sputa of patients diagnosed with tuberculosis. Sputa were tested for antibodies to HIV using OraQuick® HIV-1/2 Assay (OraSure Technologies, Inc., Bethlehem, PA, USA). The results were compared with results of serum ELISA.@*RESULTS@#Compared to serum ELISA, the OraQuick® HIV-1/2 Assay in sputum specimens reported 90% sensitivity (9/10) and 100% specificity (307/307), with a positive predictive value of 100% (95%CI: 66.37%-100.00%) and a negative predictive value of 99.68% (95%CI: 98.20%-99.99%).@*CONCLUSIONS@#This testing method may provide a useful strategy for conducting HIV surveillance in possible co-infected TB patients at peripheral centres. Since there is no investment on infrastructure, it may be possible for paramedical health professionals to carry out the test, particularly in areas with low HIV endemicity.
